Thousand Oaks Biologics Inc. and GeneQuantum Healthcare Co., Ltd. (GQ) entered into a strategic partnership focusing on the CMC development of ADC products with a core conjugation technology for more stable drug candidates.

The over 200 million RMB collaboration will allow GQ to leverage TOBio’s expertise in CMC and commercial manufacturing to advance its pharmaceutical research on ADC products and enable GQ to speed up its Biologics License Applications. Meanwhile, GQ will share with TOBio its leading enzymatic site-specific conjugation technology to provide more effective and comprehensive CDMO services to the industry.

“We are thrilled to have reached an in-depth collaboration with Thousand Oaks Biologics,” said Qin Gang, chairman of GQ. “TOBio is a cutting-edge global biopharmaceutical development and manufacturing organization, whose CMC capabilities in biologics are widely acknowledged. GQ and TOBio will collaborate closely, leveraging our respective strengths and resources, to pursue multiple cooperative projects, and to jointly accelerate the development of the ADC industry.”

Luo Shun, chairman of TOBio said, “I am very excited to establish this collaboration with GeneQuantum Healthcare. GQ’s innovative conjugation technology offers significant value and differentiated advantages in the discovery and development of ADC molecules. We believe Thousand Oaks Biologics’ competitive CMC expertise in large molecules will fully empower GeneQuantum to accelerate its product development process, making high-quality biological drugs accessible and affordable to patients.”